Literature DB >> 15123279

In vitro and in vivo production of new aminocoumarins by a combined biochemical, genetic, and synthetic approach.

Ute Galm1, Marco Aurélio Dessoy, Jürgen Schmidt, Ludger A Wessjohann, Lutz Heide.   

Abstract

The aminocoumarin antibiotics clorobiocin, novobiocin, and coumermycin A(1) are inhibitors of bacterial gyrase. Their chemical structures contain amide bonds, formed between an aminocoumarin ring and an aromatic acyl component, which is 3-dimethylallyl-4-hydroxybenzoate in the case of novobiocin and clorobiocin. These amide bonds are formed under catalysis of the gene products of cloL, novL, and couL, respectively. We first examined the substrate specificity of the purified amide synthetases CloL, NovL, and CouL for the various analogs of the prenylated benzoate moiety. We then generated new aminocoumarin antibiotics by feeding synthetic analogs of the 3-dimethylallyl-4-hydroxybenzoate moiety to a mutant strain defective in the biosynthesis of the prenylated benzoate moiety. This resulted in the formation of 32 new aminocoumarin compounds. The structures of these compounds were elucidated using FAB-MS and (1)H-NMR spectroscopy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15123279     DOI: 10.1016/j.chembiol.2004.01.012

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  11 in total

1.  Enzymatic basis of "hybridity" in thiomarinol biosynthesis.

Authors:  Zachary D Dunn; Walter J Wever; Nicoleta J Economou; Albert A Bowers; Bo Li
Journal:  Angew Chem Int Ed Engl       Date:  2015-02-26       Impact factor: 15.336

Review 2.  What can a chemist learn from nature's macrocycles?--a brief, conceptual view.

Authors:  Ludger A Wessjohann; Eelco Ruijter; Daniel Garcia-Rivera; Wolfgang Brandt
Journal:  Mol Divers       Date:  2005       Impact factor: 2.943

3.  Activity screening of carrier domains within nonribosomal peptide synthetases using complex substrate mixtures and large molecule mass spectrometry.

Authors:  Pieter C Dorrestein; Jonathan Blackhall; Paul D Straight; Michael A Fischbach; Sylvie Garneau-Tsodikova; Daniel J Edwards; Shaun McLaughlin; Myat Lin; William H Gerwick; Roberto Kolter; Christopher T Walsh; Neil L Kelleher
Journal:  Biochemistry       Date:  2006-02-14       Impact factor: 3.162

4.  Optimizing glycosyltransferase specificity via "hot spot" saturation mutagenesis presents a catalyst for novobiocin glycorandomization.

Authors:  Gavin J Williams; Randal D Goff; Changsheng Zhang; Jon S Thorson
Journal:  Chem Biol       Date:  2008-04

Review 5.  Metabolic engineering for the production of natural products.

Authors:  Lauren B Pickens; Yi Tang; Yit-Heng Chooi
Journal:  Annu Rev Chem Biomol Eng       Date:  2011       Impact factor: 11.059

6.  A three enzyme pathway for 2-amino-3-hydroxycyclopent-2-enone formation and incorporation in natural product biosynthesis.

Authors:  Wenjun Zhang; Megan L Bolla; Daniel Kahne; Christopher T Walsh
Journal:  J Am Chem Soc       Date:  2010-05-12       Impact factor: 15.419

7.  Heterologous expression of novobiocin and clorobiocin biosynthetic gene clusters.

Authors:  Alessandra S Eustáquio; Bertolt Gust; Ute Galm; Shu-Ming Li; Keith F Chater; Lutz Heide
Journal:  Appl Environ Microbiol       Date:  2005-05       Impact factor: 4.792

8.  The ATP-dependent amide ligases DdaG and DdaF assemble the fumaramoyl-dipeptide scaffold of the dapdiamide antibiotics.

Authors:  Marie A Hollenhorst; Jon Clardy; Christopher T Walsh
Journal:  Biochemistry       Date:  2009-11-03       Impact factor: 3.162

9.  Antimicrobial and DNA gyrase-inhibitory activities of novel clorobiocin derivatives produced by mutasynthesis.

Authors:  Ute Galm; Stefanie Heller; Stuart Shapiro; Malcolm Page; Shu-Ming Li; Lutz Heide
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

10.  Simocyclinone D8, an inhibitor of DNA gyrase with a novel mode of action.

Authors:  Ruth H Flatman; Alison J Howells; Lutz Heide; Hans-Peter Fiedler; Anthony Maxwell
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.